PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)
Traumatic Brain InjuryThis is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria
The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following:
i) Patients with severe TBI defined as GCS of ≤8, or
ii) Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following:
1. Requiring invasive mechanical ventilation at the time of screening
2. Increased ICB on repeat CT scan compared to initial CT scan
iii) Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury
iv) ≥ 18 years of age
Exclusion Criteria
All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:
i) Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products
ii) Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN (Dalteparin) is positive
iii) Known septic endocarditis
iv) Uncontrollable active bleeding
v) Known major blood clotting disorders
vi) Known acute gastroduodenal ulcer (with active bleeding)
vii) Severe uncontrolled hypertension (i.e. BP\>210 despite medications)
viii) Known diabetic or hemorrhagic retinopathy
ix) Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period
x) Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure)
xi) Known presence of irreversible coagulopathies
xii) Known Pregnancy
xiii) Participants extremely low weight (\<45 kg), or extremely high weight (\>120kg)
xiv) Not expected to survive more than 48 hours from admission
Study Location
Vancouver General Hospital
Vancouver General HospitalVancouver, British Columbia
Canada
Contact Study Team
Donald Griesdale, MD, MPH, FRCPC
The Ottawa Hospital
The Ottawa HospitalOttawa, Ontario
Canada
Contact Study Team
Shane English, MD, MSc, FRCPC
University of Alberta Hospital
University of Alberta HospitalEdmonton, Alberta
Canada
Contact Study Team
Jim Kutsogiannis, MD, MHS, FRCPC
Kingston General Hospital
Kingston General HospitalKingston, Ontario
Canada
Contact Study Team
Gordon Boyd, MD, PhD, FRCPC
Royal University Hospital
Royal University HospitalSaskatoon, Saskatchewan
Canada
Contact Study Team
Gary Hunter, MD, FRCPC, CSCN (EEG)
Foothills Medical Centre
Foothills Medical CentreCalgary, Alberta
Canada
Contact Study Team
Andreas Kramer, MD
Queen Elizabeth II Health Sciences Centre
Queen Elizabeth II Health Sciences CentreHalifax, Nova Scotia
Canada
Contact Study Team
Sean Christie, MD, FRCSC
Laurel Murphy, MD
Sunnybrook Health Science Centre
Sunnybrook Health Science CentreToronto, Ontario
Canada
Contact Study Team
Damon Scales, MD, PhD, FRCPC
Farhad Pirouzmand, MD, MSc, FRCSC
Royal Alexandra Hospital
Royal Alexandra HospitalEdmonton, Alberta
Canada
Contact Study Team
Jim Kutsogiannis, MD, MHS, FRCPC
Hamilton Health Sciences Centre
Hamilton Health Sciences CentreHamilton, Ontario
Canada
Contact Study Team
Paul Engels, MD
Sunjay Sharma, MD, MSc, FRCSC, FACS
Unity Health Toronto
Unity Health TorontoToronto, Ontario
Canada
Contact Study Team
Michael Cusimano, MD, MHPE, FRCS, PhD
- Study Sponsored By
- Sunnybrook Health Sciences Centre
- Participants Required
- More Information
- Study ID:
NCT03559114